Morgan Stanley raised the firm’s price target on Alnylam (ALNY) to $370 from $360 and keeps an Equal Weight rating on the shares.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALNY:
- Alnylam price target lowered to $447 from $448 at Bernstein
- Outside Review Warns Alnylam Pharmaceuticals Stock Carries High Risk of Significant Losses
- Alnylam Earnings Call Highlights TTR-Fueled Breakout
- Alnylam reports Q1 EPS $1.99, consensus $1.47
- Myles Minter Reiterates Buy on Alnylam After Strong Beat, Reaffirmed 2026 Outlook, and Advancing TRITON Phase III Pipeline